Chromium
Also called: chromium picolinate, chromium nicotinate, trivalent chromium
Trivalent chromium is a trace element present in many foods; it might potentiate insulin action. Supplements supply chromium picolinate, nicotinate, polynicotinate, chloride or histidinate. Hexavalent chromium is a toxic industrial form.
- Category
- Mineral
- Forms
- Chromium picolinate, nicotinate, polynicotinate, chloride, histidinate
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-28
Class 1 Well studied in people. NIH ODS describes a meta-analysis of 5 randomized trials (268 women with polycystic ovary syndrome) comparing supplemental chromium, mostly chromium picolinate, with placebo or metformin, and a 2019 meta-analysis of 21 chromium trials (1,316 adults with overweight or obesity). [1]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BBlood sugar and weight3 topics
CHeart and blood vessels1 topic
CHormones and reproduction1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Blood glucose in type 2 diabetes | C | A 2019 review of 58 trials found slightly lower fasting glucose and HbA1c of unclear clinical significance; a 24-week trial (137 people, 1,000 mcg/day picolinate) found no significant effect. [1] |
| Body weight and body fat | B | A 2019 meta-analysis (21 trials, 1,316 people, 200–1,000 mcg/day, 9–24 weeks) found about 0.75 kg more weight loss than placebo; ODS says these effects have little clinical significance. [1] |
| Metabolic syndrome | C | Two trials (63 people, 500 mcg twice daily, 16 weeks; 70 people, 300 mcg/day, 24 weeks) showed no meaningful benefit. [1] |
| Polycystic ovary syndrome | C | A meta-analysis (7 trials, 351 people, 200–1,000 mcg/day) found lower BMI and free testosterone but no effect on fasting glucose; ODS describes the evidence as mixed. [1] |
| Blood lipids | C | Trials conflict; meta-analyses found no significant change in total or LDL cholesterol, with some HDL increases and triglyceride decreases. [1] |
Main constituents: Chromium picolinate (about 1.2% absorbed); chromium chloride (about 0.4%) [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Adult AI: men 35 mcg/day (19–50) and 30 mcg/day (51+); women 25 mcg/day (19–50) and 20 mcg/day (51+); pregnancy 30 mcg/day; lactation 45 mcg/day. No RDA (data insufficient for an EAR). [1]
- Diabetes trials used 1,000 mcg/day for 4 months to 24 weeks; weight trials used 200–1,000 mcg/day for 9–24 weeks. [1]
Upper limits
- No UL has been established; no adverse effects have been linked to high chromium intakes from food or supplements, but the Food and Nutrition Board advised caution because data are limited. [1]
Safety and side effects
- Liver (NIH LiverTox)See details
NIH ODS: according to isolated case reports, chromium supplements might cause liver dysfunction (among other effects), and people with renal and liver disease might be …
Details and sources - Pregnancy and breastfeedingNIH ODS gives Adequate Intakes only: 30 mcg/day in pregnancy and 45 mcg/day in lactation (ages 19–50); no Tolerable Upper Intake Level has been set.
1 statement in the profile.
Details and sources - Interactions with medicines4 listed
Insulin; Metformin and other antidiabetes medications; Levothyroxine; Antacids
Details and sources - Cancer evaluations (IARC, NTP)2 found
Each names the exact material tested, which may differ from a supplement.
Details and sources - FDA new dietary ingredient notifications5 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
Interactions
| With | What happens |
|---|---|
| Insulin | Taking chromium with insulin could increase the risk of hypoglycemia. [1] |
| Metformin and other antidiabetes drugs | Possible additive glucose-lowering effect and hypoglycemia risk. [1] |
| Levothyroxine | In a small study, chromium picolinate taken at the same time decreased levothyroxine absorption over 6 hours. [1] |
| Antacids | Inhibit chromium absorption; ascorbic acid and aspirin increase it. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- Hexavalent chromium is a toxic by-product of manufacturing; the ODS fact sheet covers only trivalent chromium. [1]
Regulatory status
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Trivalent (+3) chromium as chromium picolinate, nicotinate, polynicotinate, chloride or histidinate Mineral (trivalent chromium compounds) [P4]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 5 entries naming chromium (earliest NDI 485 submitted 2007-10-03; most recent NDI 927 submitted 2016-05-10). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P1]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- IARC: Chromium (III) compounds, Group 3 (not classifiable), Volume 49 (1990); chromium, metallic, Group 3. Chromium (VI) compounds are Group 1 (carcinogenic to humans; Volumes Sup 7, 49, 100C, 2012). [P3]
- NIH ODS describes chromium as trivalent (+3) chromium, a trace element naturally present in many foods and available as a dietary supplement, and hexavalent (+6) chromium as a toxic by-product of stainless steel and other manufacturing processes; the fact sheet covers only trivalent chromium. [P4]
- NTP TR-556 (2010), chromium picolinate monohydrate in feed for 2 years: equivocal evidence of carcinogenic activity in male F344/N rats (preputial gland adenoma); no evidence in female rats or in male or female B6C3F1 mice at 2,000, 10,000 or 50,000 ppm. [P5]
Liver (NIH LiverTox)
- NIH ODS: according to isolated case reports, chromium supplements might cause liver dysfunction (among other effects), and people with renal and liver disease might be susceptible to adverse effects from high chromium intakes. No LiverTox chapter on chromium was found. [P4]
Interactions with medicines
- Insulin: NIH ODS: taking chromium concomitantly with insulin could increase the risk of hypoglycemia. [P4]
- Metformin and other antidiabetes medications: NIH ODS: chromium supplements might have an additive effect with metformin or other antidiabetes medications. [P4]
- Levothyroxine: NIH ODS: chromium picolinate taken at the same time decreases levothyroxine absorption over 6 hours. [P4]
- Antacids: NIH ODS: oxalate and antacids inhibit chromium absorption. [P4]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- Vitamin C (ascorbic acid): NIH ODS: ascorbic acid increases chromium absorption. [P4]
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of the dietary ingredient — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants a petition for an exemption under 111.75(a)(1)(ii). [P2]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- NIH ODS: dietary chromium absorption is low, from about 0.4% to 2.5%; ascorbic acid and prostaglandin inhibitors such as aspirin increase absorption, whereas oxalate and antacids inhibit it. [P4]
- NIH ODS: the proportion of chromium absorbed from chromium picolinate is about 1.2%, whereas that from chromium chloride is about 0.4% (the fact sheet does not state the study population). [P4]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- NIH ODS gives Adequate Intakes only: 30 mcg/day in pregnancy and 45 mcg/day in lactation (ages 19–50); no Tolerable Upper Intake Level has been set. [P4]
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- eCFR. 21 CFR 111.75 What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- IARC Monographs. List of Classifications (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- NIH Office of Dietary Supplements. Chromium: Fact Sheet for Health Professionals (updated June 2, 2022), 2022-06-02. ods.od.nih.gov
- National Toxicology Program. TR-556: Toxicology and Carcinogenesis Studies of Chromium Picolinate Monohydrate in F344/N Rats and B6C3F1 Mice (Feed Studies) (2010), 2010. ntp.niehs.nih.gov
Sources
- NIH Office of Dietary Supplements. Chromium: Fact Sheet for Health Professionals (updated 2022-06-02), 2022-06-02. ods.od.nih.gov
- US Food and Drug Administration. Qualified Health Claims: Letters of Enforcement Discretion (content current as of 03/28/2024), 2024-03-28. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in mineral: Boron · Calcium · Copper · Iodine · Iron · Magnesium · Manganese · Molybdenum · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.